Sign Up Today and Learn More About PathAI Stock
Invest in or calculate the value of your shares in PathAI or other pre-IPO companies through EquityZen's platform.
PathAI Stock (PAHI)
PathAI is developing cutting-edge technology that promises to better diagnose—and treat—some of today's most challenging diseases.
About PathAI Stock
Founded
2016
Headquarters
Boston, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
PathAI’s services solve the most challenging pathology problems faced by the research and pharmaceutical industry. The PathAI platform provides end-to-end automation for reliable, scalable, and cost-effective long-term solutions. PathAI is developing technology that assists pathologists in making rapid and accurate diagnoses for every patient, every time. The company was founded in 2016 and based in Boston, Massachusetts.
PathAI Press Mentions
Stay in the know about the latest news on PathAI
FDA grants breakthrough designation to PathAI for pathology solution
medicaldevice-network • Mar 05, 2026
Labcorp collaborates with PathAI to deploy FDA-cleared pathology platform
pro • Feb 24, 2026
Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide
prnewswire • Feb 23, 2026
Systems and methods for assessing liver pathology
patents • Feb 01, 2026
Multi-resolution foundation model for pathology
patents • Feb 01, 2026
Investors in PathAI
Discover investors in PathAI stock and explore their portfolio companies
PathAI Management
Leadership team at PathAI
Co-founder & CEO
Andrew Beck
Co-founder & CTO
Aditya Khosla
Join now and verify your accreditation status to gain access to:
- PathAI Current Valuation
- PathAI Stock Price
- PathAI Management
- Available deals in PathAI and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- PathAI Cap Table and Funding History by Share Class and Liquidity Preferences
- PathAI Revenue and Financials
- PathAI Highlights
- PathAI Business Model
- PathAI Risk Factors
- PathAI Research Report from SACRA Research
Trading PathAI Stock
How to invest in PathAI stock?
Accredited investors can buy pre-IPO stock in companies like PathAI through EquityZen funds. These investments are made available by existing PathAI shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell PathAI stock?
Shareholders can sell their PathAI stock through EquityZen's private company marketplace. EquityZen's network includes over 430K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 52K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
